These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Hermann M; Ruschitzka F Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448 [TBL] [Abstract][Full Text] [Related]
3. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Hermann M; Ruschitzka F Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196 [TBL] [Abstract][Full Text] [Related]
4. [Coxibes--bullying of a drug class?]. Müller P; Simon B MMW Fortschr Med; 2008 Jun; 150 Suppl 2():63-4. PubMed ID: 18712125 [No Abstract] [Full Text] [Related]
5. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Woodruff T Intern Med J; 2006 Dec; 36(12):797-8; author reply 798-9. PubMed ID: 17096747 [No Abstract] [Full Text] [Related]
6. What price pain relief? Hochman JS; Shah NR Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335 [No Abstract] [Full Text] [Related]
8. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [TBL] [Abstract][Full Text] [Related]
9. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957 [TBL] [Abstract][Full Text] [Related]
10. [Drug safety of NSAIDs and COX-2 inhibitors]. Herdegen T; Fauler J Med Monatsschr Pharm; 2006 Apr; 29(4):122-8. PubMed ID: 16628961 [TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. Moore RA; Derry S; Phillips CJ; McQuay HJ BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784 [TBL] [Abstract][Full Text] [Related]
12. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
14. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do? Lazzaroni M; Battocchia A; Bianchi Porro G Dig Liver Dis; 2007 Jun; 39(6):589-96. PubMed ID: 17459794 [TBL] [Abstract][Full Text] [Related]
15. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Mukherjee D Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915 [TBL] [Abstract][Full Text] [Related]
16. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Hur C; Chan AT; Tramontano AC; Gazelle GS Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709 [TBL] [Abstract][Full Text] [Related]
17. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]. Nurmohamed MT Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165 [No Abstract] [Full Text] [Related]
19. To use or not to use: the dilemma of NSAIDs and craniotomy. Umamaheswara Rao GS; Gelb AW Eur J Anaesthesiol; 2009 Aug; 26(8):625-6. PubMed ID: 19584610 [No Abstract] [Full Text] [Related]
20. The COX-2 inhibitors--an update. Furberg CD Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896 [No Abstract] [Full Text] [Related] [Next] [New Search]